Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979 | 0.96 | — | — | |
| SCHEMBL4727402 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Ammonia Solution, Strong SCHEMBL6136995 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Fluoride SCHEMBL1025918 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| SCHEMBL3210302 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Hydrochloric Acid SCHEMBL366444 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Fluoride SCHEMBL73856 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Trimethylammonium SCHEMBL4940105 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL4787789 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| Dimethylamine SCHEMBL6889985 | 0.83 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2920156-B9 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2017-04-19 | — | — | EP | claimed |
| EP-2920156-B1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2016-12-07 | — | — | EP | claimed |
| US-11708345-B2 | Continuous method for preparing carbonate esters | UCHICAGO ARGONNE, LLC (US) | 2023-07-25 | — | — | US | disclosed |
| CN-115335383-A | Cyclic compound for organic electroluminescent device | 默克专利有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-110878057-B | Method for preparing Raxinader | 江苏宇田医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20210276969-A1 | CONTINUOUS METHOD FOR PREPARING CARBONATE ESTERS | UCHICAGO ARGONNE, LLC (US) | 2021-09-09 | — | — | US | disclosed |
| US-11028065-B1 | Continuous method for preparing carbonate esters | UCHICAGO ARGONNE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| CN-110878057-A | Method for preparing Raxinader | 江苏宇田医药有限公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3037416-A1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2326624-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010027889-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-0731797-A1 | PARAMAGNETIC CHELATES FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSIS | BRACCO S.p.A. (IT) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015319-A1 | PARAMAGNETIC CHELATES FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSIS | BRACCO S.P.A. (IT) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | ALDH1A1 1643/4885TAAR1 3753/4885 |
| US-11708345-B2 | Continuous method for preparing carbonate esters | CYP2E1, CYP2F1, CYP2C19 | ALDH1A1 52/4885TAAR1 2080/4885 |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | ALDH1A1 1643/4885TAAR1 3753/4885 |
| US-11028065-B1 | Continuous method for preparing carbonate esters | CYP2E1, CYP2F1, CYP2C19 | ALDH1A1 52/4885TAAR1 2080/4885 |
| US-20210276969-A1 | CONTINUOUS METHOD FOR PREPARING CARBONATE ESTERS | CYP2E1, CYP2F1, CYP2C19 | ALDH1A1 52/4885TAAR1 2080/4885 |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | ALDH1A1 53/4885TAAR1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.